Expand INKT Menu
INKT MENU

INKT Latest Press Releases

-- March 17, 2026 --

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs Globe Newswire 7:30 AM

-- March 10, 2026 --

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers Globe Newswire 5:30 AM
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology Business Wire 5:00 AM

-- February 3, 2026 --

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia Globe Newswire 9:30 PM

-- January 8, 2026 --

MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease Globe Newswire 12:00 PM

-- November 20, 2025 --

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors Globe Newswire 11:42 AM

-- November 14, 2025 --

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation Globe Newswire 7:30 AM

-- November 7, 2025 --

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 Globe Newswire 9:00 AM

-- November 5, 2025 --

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development Globe Newswire 9:07 AM

-- October 30, 2025 --

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting Globe Newswire 9:00 AM
Market Data Delayed 15 Minutes